Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The conventional peritoneal dialysis (PD) solution from Fresenius Medical Care is a standard-of-care dialysis fluid used for the management of chronic renal failure. These solutions are typically glucose-based and are characterized by an acidic pH (approximately 5.5) and the presence of glucose degradation products (GDPs), which result from the heat-sterilization process. They function by being introduced into the peritoneal cavity, where the high glucose concentration creates an osmotic gradient that draws excess water and uremic toxins from the blood across the peritoneal membrane. These solutions are available in various formulations (e.g., CAPD 2, CAPD 17) with differing glucose and calcium concentrations to meet individual patient needs. While effective for renal replacement therapy in both Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD), they are often used as clinical trial comparators for newer biocompatible solutions that aim to better preserve the peritoneal membrane and residual renal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fresenius Conventional Peritoneal Dialysis Solution.